April 28, 2020 / 11:04 AM / a month ago

Merck profit rises, cuts 2020 forecast over COVID-19 uncertainty

April 28 (Reuters) - Merck & Co Inc on Tuesday posted a 10.4% rise in first-quarter profit, helped by strong sales of cancer therapy Keytruda, but the drugmaker lowered its 2020 profit forecast due to uncertainty from the COVID-19 pandemic.

The company now expects its full-year adjusted profit forecast to be in the range of $5.17 to $5.37 per share, down from its prior estimates of between $5.62 and $5.77 per share.

Net income attributable to shareholders rose to $3.22 billion, or $1.26 per share, in the quarter, from $2.92 billion, or $1.12 per share, a year earlier. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below